Citi analyst anticipates FDA experts will favor exa-cel, fol...

Citi analyst anticipates FDA experts will favor exa-cel, following last year's positive feedback on Zynteglo and Skysona. Beam shares may see a 10%-30% lift post favorable FDA comments. Predicts a promising future for Editas Medicine based on upcoming AdCom and expected data readout for EDIT-301.